Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292580 | 0.93 | GABRG2 (0.65) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6292893 | 0.93 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6292932 | 0.89 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL2658938 | 0.89 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6292963 | 0.88 | GABRG2 (0.60) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6294015 | 0.88 | GABRG2 (0.68) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6298092 | 0.84 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6292890 | 0.84 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL5229372 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6297291 | 0.82 | GABRG2 (0.48) | GABRG2GABRB3GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872720-B2 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-03-29 | — | — | US | claimed |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-27 | — | — | US | claimed |
| EP-1282623-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-02-12 | — | — | EP | claimed |
| WO-2001077111-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-10-18 | — | — | WO | claimed |
| US-6872720-B2 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-03-29 | — | — | US | disclosed |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA4 | GABRG2 15/4885GABRB3 7/4885GABRA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.